Niagen Bioscience (NAGE) Q1 2026 earnings review
Growth Hits a Wall as Operations Burn Cash
Niagen Bioscience's top-line growth decelerated dramatically to just 3% YoY in Q1 2026, a stark contrast to the 30%+ growth trajectory seen throughout 2025. While headline Net Income rose to $6.3M, this optical illusion was entirely driven by a $4.8M one-time gain from selling the Analytical Reference Standards segment. Stripping out the divestiture, the underlying business is under pressure: Adjusted EBITDA declined to $3.8M, operating expenses surged 26%, and operating cash flow reversed into negative territory (-$1.2M) due to a heavy inventory build. Although the direct-to-consumer e-commerce engine remains functional, the B2B segment is dragging down the aggregate performance.
🐂 Bull Case
The core Tru Niagen E-commerce channel grew 14% YoY to $19.2M, proving that direct-to-consumer demand for NAD+ supplements remains robust despite wider business lumpiness.
The launch of a telehealth platform for at-home Niagen Plus injections and the introduction of topical skincare products opens high-margin, recurring revenue streams outside the crowded oral supplement space.
🐻 Bear Case
Total revenue growth plummeted from 38% in 25Q1 to just 3% this quarter. B2B and Watson's orders cratered 32% YoY, indicating extreme channel volatility.
GAAP Net Income only grew because of a $4.8M asset sale. Without it, rising Sales & Marketing and General & Administrative expenses would have resulted in a significant YoY profitability decline.
⚖️ Verdict: 🔴
Bearish. A severe deceleration in revenue growth, declining underlying profitability, and a reversal to negative cash flow outweigh the company's aggressive expansion into new product categories. Management's guidance requires a steep re-acceleration in the back half of the year.
Key Themes
Watson's and B2B Channel Reversing
The Watson's & Other B2B segment plummeted 32% YoY to $3.2M. While management often cites the 'lumpy' nature of B2B ordering, this sharp decline is the primary anchor dragging down aggregate Tru Niagen growth. This lack of predictability makes forecasting highly difficult and masks the stability of the E-commerce side.
Cash Flow and Working Capital Squeeze
Operating Cash Flow is reversing. Q1 26 saw a $1.2M burn compared to a $7.9M inflow a year ago. This was driven by a heavy working capital drag (-$5.0M), specifically a $3.6M inventory build and a $3.3M increase in trade receivables. Management states inventory is at a 'peak level' to support planned commercial activities, meaning cash flow recovery relies entirely on successfully selling through this stockpile.
Telehealth Platform and Niagen Plus Rollout
The company officially launched its clinician-directed telehealth platform, allowing eligible patients to access prescription Niagen at-home injection kits. Paired with a new 503B compounding partner, this bypasses the clinic bottleneck, addressing management's prior concern that high clinic administration prices limit volume. This direct-to-patient approach is a crucial growth driver for the second half of 2026.
IP Moat Fortified by USP Monograph
Niagen established the first United States Pharmacopeia (USP) monograph for nicotinamide riboside chloride (NRCL). This acts as a significant regulatory moat. By establishing a standardized quality benchmark, Niagen forces competitors—especially the gray market NMN space—to compete on validated scientific standards, an arena where Niagen currently holds the strongest patent and clinical portfolio.
Aggressive Spike in Operating Expenses
Operating Expenses ballooned 26% YoY to $18.4M. Sales & Marketing rose $1.6M due to heightened advertising, while G&A jumped $2.1M primarily from increased share-based compensation. While management expects this spending to drive future customer acquisition, the immediate result is margin compression at the operating level.
Other KPIs
Stable YoY. Remained effectively flat compared to 63.4% in 25Q1. Favorable business mix and supply chain efficiencies continue to hold the line, though the massive margin expansion seen in mid-2025 has leveled off.
Accelerating. The Board increased the share repurchase authorization to $20 million, and the company bought back $2.4 million during the quarter. Utilizing balance sheet cash for buybacks provides some downside protection for the stock amidst decelerating operational growth.
Guidance
Decelerating. Excludes the divested segment. To achieve the 12.5% midpoint after a 5% (adjusted) growth rate in Q1, the company implies a significant re-acceleration in Q2-Q4. This relies heavily on the success of the new telehealth platform and a rebound in B2B orders.
Reversing prior guidance. Management previously guided for S&M to be stable as a percentage of sales. The updated outlook explicitly states S&M will increase both in absolute dollars and as a percentage of sales to support new verticals.
Slightly improved outlook. Previously guided to increase by $4M to $5M. The structural increase is still driven by legal expenses and higher share-based compensation.
Key Questions
B2B Visibility
Watson's and other B2B sales dropped severely this quarter. Is this merely a timing issue with purchase orders, or are there structural demand issues emerging in the Asian distribution channels?
Path to Free Cash Flow
Inventory is stated to be at 'peak levels.' What is the exact timeline for burning down this $24M inventory pile, and when should investors expect a return to positive operating cash flow?
Telehealth Economics
With the launch of the Niagen Plus telehealth platform, what are the expected Customer Acquisition Costs (CAC) and gross margins for the at-home injection kits compared to the core E-commerce Tru Niagen pills?